| Dr Kyle Willson, DPM | |
|
975 Sereno Dr, Vallejo, CA 94589-2441 | |
| (707) 651-1000 | |
| Not Available |
| Full Name | Dr Kyle Willson |
|---|---|
| Gender | Male |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 975 Sereno Dr, Vallejo, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467868885 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | EL6700 (California) | Primary |
| Provider Name | Sutter Bay Medical Foundation |
|---|---|
| Provider Type | Part B Supplier - Ambulatory Surgical Center |
| Provider Identifiers | NPI Number: 1982845186 PECOS PAC ID: 4284538778 Enrollment ID: O20090501000247 |
News Archive
Serotonin, known as the "happiness" neurotransmitter, is a chemical found in the body responsible for feelings of well-being. But serotonin isn't the only chemical that binds to the 13 serotonin receptors found on the surface of cells. Far from it. Many approved drugs also bind to serotonin receptors.
US study results show that the genetic abnormality underlying the pediatric condition methyl-CpG binding protein 2 duplication syndrome also causes immune dysfunction.
Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a new "first response" mechanism that the immune system uses to respond to infection. The findings challenge the current understanding of immunity and could lead to new strategies for boosting effectiveness of all vaccines. The study, conducted in mice, published online today in the journal Immunity.
Quintiles today announced a strategic alliance with leading global pharmaceutical company Eisai Co., Ltd. (Tokyo, Japan) to develop six potential oncology products in Eisai's R&D pipeline. Under the terms of the agreement, Quintiles' oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. A key goal of the alliance is to determine the efficacy of the products in the shortest possible time in order to bring therapies to market faster for the benefit of cancer patients worldwide.
A promising new drug for sepsis is on the horizon thanks to new funding from the British Heart Foundation, which could help take the laboratory discovery into the clinic.
› Verified 9 days ago
| Provider Name | Sutter Bay Medical Foundation |
|---|---|
| Provider Type | Part B Supplier - Ambulatory Surgical Center |
| Provider Identifiers | NPI Number: 1104067115 PECOS PAC ID: 4284538778 Enrollment ID: O20090501000456 |
News Archive
Serotonin, known as the "happiness" neurotransmitter, is a chemical found in the body responsible for feelings of well-being. But serotonin isn't the only chemical that binds to the 13 serotonin receptors found on the surface of cells. Far from it. Many approved drugs also bind to serotonin receptors.
US study results show that the genetic abnormality underlying the pediatric condition methyl-CpG binding protein 2 duplication syndrome also causes immune dysfunction.
Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a new "first response" mechanism that the immune system uses to respond to infection. The findings challenge the current understanding of immunity and could lead to new strategies for boosting effectiveness of all vaccines. The study, conducted in mice, published online today in the journal Immunity.
Quintiles today announced a strategic alliance with leading global pharmaceutical company Eisai Co., Ltd. (Tokyo, Japan) to develop six potential oncology products in Eisai's R&D pipeline. Under the terms of the agreement, Quintiles' oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. A key goal of the alliance is to determine the efficacy of the products in the shortest possible time in order to bring therapies to market faster for the benefit of cancer patients worldwide.
A promising new drug for sepsis is on the horizon thanks to new funding from the British Heart Foundation, which could help take the laboratory discovery into the clinic.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kyle Willson, DPM 136 Breakwater Way, Vacaville, CA 95688-0106 Ph: (707) 685-4686 | Dr Kyle Willson, DPM 975 Sereno Dr, Vallejo, CA 94589-2441 Ph: (707) 651-1000 |
News Archive
Serotonin, known as the "happiness" neurotransmitter, is a chemical found in the body responsible for feelings of well-being. But serotonin isn't the only chemical that binds to the 13 serotonin receptors found on the surface of cells. Far from it. Many approved drugs also bind to serotonin receptors.
US study results show that the genetic abnormality underlying the pediatric condition methyl-CpG binding protein 2 duplication syndrome also causes immune dysfunction.
Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a new "first response" mechanism that the immune system uses to respond to infection. The findings challenge the current understanding of immunity and could lead to new strategies for boosting effectiveness of all vaccines. The study, conducted in mice, published online today in the journal Immunity.
Quintiles today announced a strategic alliance with leading global pharmaceutical company Eisai Co., Ltd. (Tokyo, Japan) to develop six potential oncology products in Eisai's R&D pipeline. Under the terms of the agreement, Quintiles' oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. A key goal of the alliance is to determine the efficacy of the products in the shortest possible time in order to bring therapies to market faster for the benefit of cancer patients worldwide.
A promising new drug for sepsis is on the horizon thanks to new funding from the British Heart Foundation, which could help take the laboratory discovery into the clinic.
› Verified 9 days ago
Napa Solano Foot And Ankle Podiatrist Medicare: Medicare Enrolled Practice Location: 1460 N Camino Alto, Suite 101, Vallejo, CA 94589 Phone: 707-644-4049 Fax: 707-644-4687 | |
Ronald Delosreyes Paterno, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 975 Sereno Dr, Vallejo, CA 94589 Phone: 707-651-1000 | |
Dr. Monica Jung, Podiatrist Medicare: Medicare Enrolled Practice Location: 975 Sereno Dr, Vallejo, CA 94589 Phone: 707-651-1000 | |
Stephen Haynam, Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 975 Sereno Dr, Vallejo, CA 94589 Phone: 707-651-3338 | |
Ninveh Omlin, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 975 Sereno Dr, Vallejo, CA 94589 Phone: 707-651-5033 Fax: 707-651-3685 | |
Lance Vanwoy, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 975 Sereno Dr, Vallejo, CA 94589 Phone: 707-651-1000 | |
Nicholas Gan Tan, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 975 Sereno Dr, Vallejo, CA 94589 Phone: 909-633-2881 |